ABBOTINDIA · Abbott India Ltd · Biotechnology & Drugs
ABBOTINDIA · Abbott India Ltd · Biotechnology & Drugs
As of 05 Nov close
52-week range
13.2% below 52-week high
52-week range: as of 05 Nov 2026 close.
Price chartDaily closes on the stock page.
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Full signal detail →Fundamentals as of 15 Sep 2026 · the company's own latest record is 52 days old
Revenue (latest Q)
₹1,814 Cr
Revenue YoY
PAT YoY
+17.1%
Operating margin
Revenue, last 8 quarters
P/E (TTM)
P/B
11.7
P/S (TTM)
7.8
Sector P/E
36.3
Dividend yield
+2.0%
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| ABBOTINDIA (this stock) | 33.3 | 11.7 | +23.1% | +33.8% | 0.04 | +2.0% |
| Sun Pharmaceutical Industries | 38.4 | 5.6 | +19.1% | +14.2% | 0.47 | +0.8% |
| Divi's Laboratories | 59.7 | 14.5 | +26.1% | +17.4% | 0 | +0.3% |
| Torrent Pharmaceuticals | 72.7 | 19.2 | +15.3% | +27.1% | 141.16 | +0.8% |
Promoter
stable
FII
rising 2q
MF
7.44% (-0.24pp)
falling 1q
Insider trades
No insider trades in the last 12 months.
Bulk/block deals
No bulk/block deals in the last 12 months.
News timeline
- mediumcorporate actioneconomictimes.indiatimes.com· 15 Jul 2026, 06:36 pmWarburg Pincus buys Mumbai’s pharma company Integrace in ₹1,200 crore deal
Concalls & investor presentations
AI-generatedNo concall transcripts or investor presentations recorded yet.
Governance disclosures
AI-generatedNo governance disclosures identified in ABBOTINDIA's filed documents yet.